Novogen (NASDAQ:KZIA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Novogen (NASDAQ:KZIA) to a hold rating in a report issued on Saturday morning.

Several other brokerages have also commented on KZIA. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Wednesday, October 8th. Maxim Group boosted their target price on Novogen from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Novogen presently has an average rating of “Moderate Buy” and an average target price of $16.50.

Novogen Price Performance

KZIA stock opened at $8.45 on Friday. The company’s 50-day moving average price is $7.28 and its 200 day moving average price is $7.27. Novogen has a 52 week low of $2.86 and a 52 week high of $29.30.

About Novogen

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.